Amarin Corp PLC\UK (AMRN) — SEC Filings
Amarin Corp PLC\UK (AMRN) — 30 SEC filings. Latest: 10-Q (Apr 29, 2026). Includes 20 8-K, 6 10-Q, 2 DEF 14A.
View Amarin Corp PLC\UK on SEC EDGAR
Overview
Amarin Corp PLC\UK (AMRN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Apr 29, 2026: Amarin Corp. plc filed its quarterly report (10-Q) on April 29, 2026, for the period ending March 31, 2026. The filing includes various documents such as the main 10-Q report, exhibits, and XBRL data. Amarin Corp. plc is a pharmaceutical company based in Dublin, Ireland.
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 4 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Amarin Corp PLC\UK is neutral.
Filing Type Overview
Amarin Corp PLC\UK (AMRN) has filed 6 10-Q, 20 8-K, 1 8-K/A, 2 DEF 14A, 1 10-K with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of AMRN's 27 recent filings, 3 were flagged as high-risk, 13 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $70.5M |
| Net Income | -$10.2M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Karim Mikhail
- Aaron Berg
- Patrick Holt
- Dr. Steven L. Miller
- Dr. Steven L. Smith
- Dr. Karim Mikhail
- Ms. Sarah J. Kelly
- Ms. Sarah B. Greenberg
- Mr. David M. Stack
- Ms. Anya V. Schiess
- Dr. Patrick O'Sullivan
Industry Context
The pharmaceutical industry, particularly in the cardiovascular segment, is characterized by intense competition, significant R&D investment, and stringent regulatory oversight. Companies like Amarin focus on developing and commercializing specialized therapies, often facing patent cliffs and the threat of generic entry. The market for cardiovascular drugs is large but highly competitive, requiring strong commercial execution and robust intellectual property protection.
Top Tags
corporate-governance (6) · 10-Q (5) · pharmaceuticals (5) · financials (4) · delisting (4) · filing (3) · leadership-change (3) · personnel (3) · executive-appointment (3) · sec-filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Period End Date | 2026-03-31 | The end date of the reporting period for the 10-Q. |
| Filing Date | 2026-04-29 | The date the 10-Q was officially filed with the SEC. |
| Net Loss | $10.2M | for the three months ended June 30, 2025, a 59.8% improvement from $25.4 million in 2024 |
| Total Revenues | $70.5M | for the three months ended June 30, 2025, up from $68.2 million in 2024 |
| Product Sales | $135.1M | for the six months ended June 30, 2025, an increase from $130.5 million in 2024 |
| Licensing Revenue | $1.5M | from HLS Therapeutics Inc. for the six months ended June 30, 2025 |
| Revenue | N/A | Specific revenue figures for the quarter are not directly extracted but are detailed within the 10-Q. |
| Net Income/Loss | N/A | Specific net income or loss figures for the quarter are not directly extracted but are detailed within the 10-Q. |
| Total Assets | N/A | Total assets as of March 31, 2025, are detailed within the 10-Q. |
| Performance Year | 2024 | Executive compensation details are for the 2024 fiscal year. |
| Reporting Period End Date | 2024-09-30 | Indicates the end of the fiscal quarter for which financial data is reported. |
| Prior Year Reporting Period End Date | 2023-09-30 | Provides a comparative point for financial performance analysis. |
| Current Year Nine-Month Period | 2024-01-01 to 2024-09-30 | Covers the operational and financial activities for the first nine months of 2024. |
| Prior Year Nine-Month Period | 2023-01-01 to 2023-09-30 | Covers the operational and financial activities for the first nine months of 2023, for comparison. |
| Previous Period End Date | 2023-06-30 | Comparison for financial reporting |
Frequently Asked Questions
What are the latest SEC filings for Amarin Corp PLC\UK (AMRN)?
Amarin Corp PLC\UK has 30 recent SEC filings from Jan 2024 to Apr 2026, including 20 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AMRN filings?
Across 30 filings, the sentiment breakdown is: 4 bearish, 25 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Amarin Corp PLC\UK SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Amarin Corp PLC\UK (AMRN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Amarin Corp PLC\UK?
Key financial highlights from Amarin Corp PLC\UK's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AMRN?
The investment thesis for AMRN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Amarin Corp PLC\UK?
Key executives identified across Amarin Corp PLC\UK's filings include Karim Mikhail, Aaron Berg, Patrick Holt, Dr. Steven L. Miller, Dr. Steven L. Smith and 6 others.
What are the main risk factors for Amarin Corp PLC\UK stock?
Of AMRN's 27 assessed filings, 3 were flagged high-risk, 13 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Amarin Corp PLC\UK?
Forward guidance and predictions for Amarin Corp PLC\UK are extracted from SEC filings as they are enriched.